SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is trending due to community frustration regarding two capital raises: a $3 billion convertible note offering and an at-the-market equity program to sell up to 35 million shares. Traders expressed significant bearish sentiment, describing the timing of the announcement as a "rugpull" that halted a positive day of trading, while some noted that while dilutive, the capital is intended to support the company's objective of achieving an investment-grade credit profile.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

The community is debating the S&P 500's resilience following a rate hike, with many traders expressing disbelief at the rapid overnight rebound that erased losses. While bearish sentiment remains high due to concerns over bond yields, energy costs, and the Fed's hawkish policy path, bulls are interpreting the market's recovery as a sign of underlying strength.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

The community is debating the impact of the Federal Reserve's recent interest rate hike, with traders split between viewing the move as a necessary step to combat inflation and a 'policy mistake' that could harm economic growth. Discussions are highly polarized, with many reacting to the 'higher-for-longer' narrative, while others focus on technical price action and potential market manipulation by algorithms.

Fluence Energy, Inc. engages in energy storage products and services, and artificial intelligence-enabled digital applications for renewables and storage. Its storage includes Smartstack, Gridstack Pro, Grisdtack, and Ultrastack. The company was founded on June 21, 2021, and is headquartered in Arlington, VA.

Fluence Energy Inc - Ordinary Shares - Class A

Fluence Energy shares are experiencing extreme volatility, recovering sharply after an initial sell-off sparked by a second consecutive fiscal 2026 guidance cut and wider-than-expected EBITDA losses. While the company attributed the revision to persistent production delays at its Houston manufacturing facility, retail traders are debating whether the stock represents a deep-value buying opportunity given strong long-term demand and backlog, or if execution failures and management's guidance credibility warrant further downside.

CleanSpark, Inc. is a bitcoin mining technology company, which engages in the management of data centers. Its operations include College Park, Norcross, Washington, Sandersville, Dalton, and Massena. The company was founded by S. Matthew Schultz and Bryan Huber on October 15, 1987 and is headquartered in Henderson, NV.

Cleanspark Inc

CleanSpark is trending as investors react to the company's recent announcement of a proposed $2.227 billion senior secured notes offering, which is intended to support its massive data center and AI infrastructure expansion. The community remains divided, with some traders expressing frustration over recent price stagnation despite Bitcoin's rally and the broader interest in data center infrastructure, while others view the pullback as a buying opportunity based on the company's long-term growth prospects.

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

Investors are closely monitoring upcoming Starship launch catalysts and potential cross-company integration with Tesla, fueling speculation about future growth and the company's valuation. While some traders remain cautious regarding share lockup expirations and macro volatility, bullish sentiment persists on the company's long-term disruptive potential in space and AI sectors.

Snap, Inc. is a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snap is trending following the unveiling of its new Specs AI assistant and augmented reality glasses, with retail sentiment shifting toward bullishness as traders analyze the potential for enterprise applications and long-term tech differentiation. While some investors remain skeptical about the product's high price point and the company's past financial performance, others point to its growing partnerships with major tech firms as a sign of a successful shift in strategy.

Generac Holdings, Inc. engages in the business of designing and manufacturing energy technology solutions. It operates under the Domestic and International segments. The Domestic segment includes the legacy Generac business and the acquisitions that are based in the United States and Canada. The International segment focuses on Generac business' Latin American export operations. The company was founded in 1959 and is headquartered in Waukesha, WI.

Generac Holdings Inc

Generac is trending following a landmark supply agreement with Amazon to provide backup power for data centers, a deal that analysts view as a major catalyst for long-term revenue growth. While some traders express caution regarding potential share dilution from warrants issued as part of the deal, the broader community sentiment remains highly bullish on the company's expansion into AI-related infrastructure.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is trending as the community debates the delayed final data readout from the Phase 3 REGAL trial, with bulls maintaining that the extended trial duration suggests superior survival in the treatment arm while skeptics cite the lack of updates during a self-imposed quiet period and negative opinion pieces as evidence of potential failure.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovance Biotherapeutics is trending as traders speculate on imminent guidance updates and positive data readouts for its lung cancer program, bolstered by the company's recent presentations at major healthcare conferences. The community sentiment remains strongly bullish, with many investors focusing on the company's improving commercial margins and potential for long-term institutional accumulation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Verastem is receiving attention following positive clinical update commentary regarding VS-7375, including favorable biomarker data and its potential as a best-in-class KRAS G12D inhibitor. While some traders are optimistic about upcoming data readouts and potential partnership opportunities, others express frustration with the stock's price performance and ongoing concerns regarding potential equity dilution.

Verastem Stock Skyrockets 121% in 3 Months: Here Is Why

VSTM shares surge 121% as Avmapki Fakzynja Co-Pack gains commercial traction and VS-7375 advances across key cancer studies.

Verastem Oncology to Unveil New Clinical Data Highlighting the Best-in-Class Potential of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, Across Pancreatic, Lung, and Colorectal Cancers

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced it will host an investor event on Wednesday, October 14, at 8:00 am ET to present initial efficacy and updated safety and...

Verastem Oncology to Participate in Upcoming September Investor Conferences

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to participate at the Wells Fargo 21st Annual Healthcare Conference on Sept. 8 in Boston and...

Verastem (VSTM) Reports Q2 Loss, Beats Revenue Estimates

Verastem (VSTM) delivered earnings and revenue surprises of +23.91% and +73.12%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today reported financial results for the second quarter ended June 30, 2026, and highlighted recent business progress. The second quarter marked...

Royalty Pharma (RPRX) Tops Q2 Earnings and Revenue Estimates

Royalty Pharma (RPRX) delivered earnings and revenue surprises of +3.94% and +1.52%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Dianthus Therapeutics, Inc. (DNTH) Reports Q2 Loss, Tops Revenue Estimates

Dianthus Therapeutics, Inc. (DNTH) delivered earnings and revenue surprises of +3.23% and +60.89%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Guardant Health (GH) Reports Q2 Loss, Tops Revenue Estimates

Guardant Health (GH) delivered earnings and revenue surprises of -5.00% and +6.01%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Beats Revenue Estimates

Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of +23.08% and +7.98%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Verastem Oncology Doses First Patient in TARGET-D 203 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Colorectal Cancer

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the first patient has been dosed in the TARGET-D 203 Phase 2 registration-directed trial evaluating VS-7375, an investigational...

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

Verastem Inc

VSTM Stock Climbs After-Hours As FDA Grants Fast Track To Lung Cancer Drug — Retail Eyes The Next Keytruda 

Equity

Neutral Sentiment

A - Strong, decisive leadership

B - Solid, but room to improve

C - Mixed, still figuring it out

D/F - Poor communication and execution

Kevin Warsh has served as Federal Reserve Chair since May 2026, following one of the most divisive Senate confirmations in Fed history, and just delivered the Fed's first rate hike since 2023. How do you grade Kevin Warsh's performance as Fed chair so far? Vote and explain your reasoning in the comments.

Kevin Warsh has been Fed chair since May. How do you grade his performance so far?

Current Price	$7.32
Prev Close	$7.34
Open	$7.35
Dividend Yield	0.00%
50-Day Moving Average	$6.65
Beta	1.24
Avg. Volume	1.84M
PE Ratio	-2.98

52-Week High	$10.82
52-Week Low	$3.43
Market Capitalization	$662.92M
EPS (Annual)	-$3.02
Price to Book	13.25
Revenue Per Employee	$303,078.43

Feed

News

Sentiment

Earnings

Fundamentals

Info

VSTM Fundamentals